Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang(St. Joseph Health System), Kristie A. Blum(Emory University), Stephen E. Spurgeon(Oregon Health & Science University), Peter Johnson(Cancer Research UK), John Radford(Manchester Academic Health Science Centre), Fong Clow(Pharmacyclics (United States)), Stephan Stilgenbauer(Universität Ulm), Bingliang Fang(The University of Texas MD Anderson Cancer Center), Jesse McGreivy(Pharmacyclics (United States)), Lori Kunkel(Pharmacyclics (United States)), Peter Martin(Northwestern University), Martin Dreyling(LMU Klinikum), Simon Rule(AstraZeneca (United Kingdom)), Ranjana H. Advani(Stanford Medicine), Betty Chang(Rigel (United States)), Joseph J. Buggy(Pharmacyclics (United States)), Brad S. Kahl(UW Health University Hospital), Jacqueline C. Barrientos(Mount Sinai Medical Center), Ewa Chmielowska(Centrum Onkologii), Jorge Romaguera(The University of Texas MD Anderson Cancer Center), André Goy(Hackensack University Medical Center), Liang Zhang(The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture), Lei Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Michael E. Williams(University of Virginia), Wojciech Jurczak(Jagiellonian University), W Wiktor-Jędrzejczak(Medical University of Warsaw), Zhishuo Ou, Kate J. Newberry(The University of Texas MD Anderson Cancer Center), Rebecca Auer(St Bartholomew's Hospital), Nancy Cheng(The University of Texas MD Anderson Cancer Center), Darrin M. Beaupre(Pharmacyclics (United States))
Cited by 1,699
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k